Volume : 09, Issue : 10, October – 2022
02.HIGH-THROUGHPUT SCREENING IN DRUG DISCOVERY
Mrs. M. S Padmaja Devi*, Dr. Prasobh. G.R, Mrs. Sheeja Rekha. A.G, Mrs. Athira. A. S, Mrs. Anila Kumari. V. S
High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to use of robots, detectors and software that regulate the whole process, enables a sequence of analyses of chemical compounds to be conducted in a short time and the resemblance of biological structures which is often related to toxicity to be defined. The HTS method is more frequently utilized in conjunction with analytical techniques such as NMR or coupled methods e.g., LC-MS/MS. Series of studies enable the establishment of the rate of affinity for targets or the level of toxicity. Moreover, researches are conducted concerning conjugation of nano-particles with drugs and the determination of the toxicity of such structures. For these purposes there are frequently used cell lines. Determination of cytotoxicity in this way leads to a significant decrease in the costs and to a reduction in the duration of the study.
Keywords: High-throughput screening (HTS), drug development, drug discovery
Cite This Article:
Please cite this article in M.S.Padmaja Devi et al, High-Throughput Screening In Drug Discovery., Indo Am. J. P. Sci, 2022; 09(10).
Number of Downloads : 10
1. Martis, E.A.; Radhakrishnan, R.; Badve, R.R. High-throughput screening: The hits and leads of drug discovery – An overview. J. Appl. Pharm. Sci. 2011, 1, 2–10.
2. Armstrong, J.W. A review of high-throughput screening approaches for drug discovery. Am. Biotechnol. Lab. 1999, 17, 26–28.
3. Fernandes, T.G.; Diogo, M.M.; Clark, D.S.; Dordick, J.S.; Cabral, J. High-throughput cellular microarray platforms: Applications in drug discovery, toxicology and stem cell research. Trends Biotechnol. 2009, 27, 342–349.
4. Fara, D.C.; Oprea, T.; Prossnitz, E.R.; Bologa, C.G.; Edwards, B.S.; Sklar, L.A. Integration of virtual and physical screening. Drug Discov. Today 2006, 3, 337–385.
5. Mayr, L.M.; Fuerst, P. The future of high-throughput screening. J. Biomol. Screen. 2008, 13, 443–448.
6. Brandish, P.E.; Chiu, C.S.; Schneeweis, J.; Brandon, N.J.; Leech, C.L.; Kornienko, O. A cell-based ultra-high-throughput screening assay for identifying inhibitors of D-amino acid oxidase. J. Biomol. Screen. 2006, 11, 481–487.
7. Kasibhatla, S.; Gourdeau, H.; Meerovitch, K.; Drewe, J.; Reddy, S.; Qiu, L.; Zhang, H.; Bergeron, F.; Bouffard, D.; Yang, Q.; et al. Discovery and mechanism of action of novel series of apoptosis inducers with potential vascular targeting activity. Mol. Cancer Ther. 2004, 3, 1365–1373
8. Chen, D.S.; Davis, M.M. Molecular and functional analysis using live cell microarrays. Curr. Opin. Chem. Biol. 2006, 10, 28–34.
9. Koh, H.L.; Yau, W.P.; Ong, P.S.; Hegde, A. Current trends in modern pharmaceutical analysis for drug discovery. Drug Discov. Today 2003, 8, 889–897.
10. Valerio, L.G. In silico toxicology for the pharmaceutical science. Toxicol. Appl. Pharmacol. 2009, 241, 356–370.
11. Hartung, T. From alternative methods to a new toxicology. Eur. J. Pharm. Biopharm. 2011, 77, 338–349.
12. Koop, R. Combinatorial biomarkers: From early toxicology assays to patient population profiling. Drug Discov. Today 2005, 10, 781–788.
13. Kavlock, R.J.; Ankley, G.; Blancato, J.; Breen, M.; Conolly, R.; Dix, D.; Houck, K.; Hubal, E.; Judson, R.; Rabinowitz, J.; et al. Computational toxicology—A state of the science mini review. Toxicol. Sci. 2008, 103, 14–27.
14. Seidle, T.; Stephens, M.L. Bringing toxicology into the 21st century: A global call to action. Toxicol. in Vitro 2009, 23, 1576–1579.
15. Richard, A.M. Future of toxicology—Predictive toxicology: An expanded view of “chemical toxicity”. Chem. Res. Toxicol. 2006, 19, 1257–1262.